The United States usually doesn’t fare very well in international health comparisons. The country’s healthcare ranks among, if not the, most expensive. The outcomes, as measured by metrics such as life expectancy at birth, are not top tier, especially when the U.S. is compared to well-off countries in Europe and Asia.
The United States usually doesn’t fare very well in international health comparisons. The country’s healthcare ranks among, if not the, most expensive. The outcomes, as measured by metrics such as life expectancy at birth, are not top tier, especially when the U.S. is compared to well-off countries in Europe and Asia.
The story with COVID-19 is similar, according to data reported recently by Kaiser Family Foundation. Among the dozen developed countries included in the foundation’s analysis, only Belgium, at 90.4 COVID-19-related deaths per 100,000 population, was worse than the U.S., at 66.5 COVID-19 deaths per 100,000. By contrast, Japan’s rate of 1.3 COVID-19 deaths per 100,000 is stunningly low, as is Australia’s (3.6 per 100,000) and Germany’s (11.7 per 100,000).
Kaiser’s ranking of the leading causes of death is also sobering. COVID-19 is on course to being the third leading cause of death in the U.S. in 2020, behind only the perennial leaders, heart disease and cancer. In Japan, COVID-19 is on track to being the 29th leading cause of death and in Germany, the 17th
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More